Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 280

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trial

Sidtis, John J., Gatsonis, Constantine, Price, Richard W., Singer, Elyse J., Collier, Ann C., Richman, Douglas D., Hirsch, Martin S., Schaerf, Frederick W., Fischl, Margaret A., Kieburtz, Karl, Simpson, David, Koch, Matthew A., Feinberg, Judith, Dafni, Urania, The Aids Clinical Trials Group·1993·Annals of Neurology

Abstract

The efficacy of two doses of zidovudine was examined for the treatment of the acquired immunodeficiency syndrome (AIDS) dementia complex in a randomized, double‐blinded, placebo‐controlled trial conducted at nine study centers. For the initial 16 weeks, 40 subjects with mild to moderate AIDS dementia complex were randomized to one of three treatment arms: 400 mg of zidovudine five times daily, 200 mg of zidovudine five times daily, or placebo five times daily. After week 16, patients initially randomized to the placebo group were rerandomized to one of the two zidovudine treatment arms. The primary efficacy end point was improvement in performance on a battery of seven neuropsychological tests; the secondary end point was improvement on a protocol neurological evaluation directed at the cardinal features of the AIDS dementia complex. For the initial 16‐week period, average z scores based on the neuropsychological test battery revealed a significant improvement in the combined treatment groups compared to the placebo group; however, when the two treatment groups were compared separately to the placebo group, only the group receiving the higher zidovudine dose exhibited significant improvement. After rerandomization of the placebo patients to one of the two treatment arms at week 16, this group also showed significant improvement in the average neuropsychological z score by week 32. These results extend previous observations that indicate a therapeutic benefit of zidovudine for the treatment of AIDS dementia complex.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.410330403

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 280

Metadata

Authors
Sidtis, J. J., Gatsonis, C., Price, R. W., Singer, E. J., Collier, A. C., Richman, D. D., Hirsch, M. S., Schaerf, F. W., Fischl, M. A., Kieburtz, K., Simpson, D., Koch, M. A., Feinberg, J., Dafni, U., & The Aids Clinical Trials Group
Venue
Annals of Neurology
Publisher
Wiley
Published
1993-04
Volume
33
Issue
4
Pages
343-349
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2156182193
Cited by
280
References
17
FWCI
17.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trial. https://app.cochat.ai/papers/10.1002/ana.410330403
The paper
Sidtis, J. J., Gatsonis, C., Price, R. W., Singer, E. J., Collier, A. C., Richman, D. D., Hirsch, M. S., Schaerf, F. W., Fischl, M. A., Kieburtz, K., Simpson, D., Koch, M. A., Feinberg, J., Dafni, U., & The Aids Clinical Trials Group. (1993). Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trial. Annals of Neurology. https://doi.org/10.1002/ana.410330403

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.